The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L04 | Immunosuppressants | |
3
|
L04A | Immunosuppressants | |
4
|
L04AJ | Complement inhibitors | |
5
|
L04AJ07 |
| Active Ingredient |
|---|
|
Crovalimab is a recombinant humanised immunoglobulin G1 (IgG1)-based monoclonal antibody that specifically binds with high affinity to component 5 (C5) of the complement system, inhibiting its cleavage into C5a and C5b and thus preventing the formation of the membrane attack complex (MAC). Crovalimab causes terminal complement activity inhibition. In patients with PNH, crovalimab inhibits terminal complement-mediated intravascular haemolysis. |
| Document | Type | Information Source | |
|---|---|---|---|
| PIASKY Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| PIASKY Solution for injection/infusion | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.